Healthcare Services

A Significant Growth Driver for the Cross-Species Organ Transplantation Market Is the Surge In Organ Failure Fueling The Growth Of The Market Due To Rising Trauma Related Multiple Organ Failure

March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Cross-Species Organ Transplantation Market Evolve From 2026 To 2030?

The cross-species organ transplantation market has shown strong growth recently. It is projected to increase from $15.2 billion in 2025 to $16.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The historical expansion of this market can be attributed to factors such as the scarcity of human donor organs, initial research efforts in xenotransplantation, enhancements in genetic engineering tools, the preclinical validation of organs derived from animals, and the rising number of individuals on transplant waiting lists.

The cross-species organ transplantation market is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $22.65 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth during the projection period include heightened clinical trial engagement in xenotransplantation, increased capital allocation towards gene-edited animal models, stronger partnerships between biotechnology companies and transplant facilities, progress in immunosuppressive treatments, and the development of more comprehensive regulatory structures for xenotransplants. Significant trends anticipated over the forecast timeframe encompass continuous improvements in genetically engineered donor organs, a heightened emphasis on methods to reduce immune rejection, the proliferation of technologies for organ preservation and perfusion, increased funding for translational xenotransplant studies, and strengthened regulatory as well as ethical supervision.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27267&type=smp

What Key Drivers Are Influencing The Growth Of The Cross-Species Organ Transplantation Market?

An increasing move towards genetic engineering is anticipated to advance the expansion of the cross-species organ transplantation market in the future. Genetic engineering involves the intentional alteration of an organism’s DNA through biotechnological methods to insert, delete, or modify particular genes. The surge in genetic engineering stems from the critical requirement to resolve organ deficits by developing animal organs better suited for human transplants. Genetic engineering facilitates the expansion of cross-species organ transplantation by allowing animal organs to be modified, thereby lessening immune rejection and rendering them viable for human transplants. As an example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific entity, reported 247 gene therapies were in Phase II by the conclusion of the first quarter of 2023; this figure rose by 5% to 260 by the end of the second quarter. Consequently, the expanding focus on genetic engineering is propelling the development of the cross-species organ transplantation market.

Which Segment Areas Are Covered In The Cross-Species Organ Transplantation Market Analysis?

The cross-species organ transplantation market covered in this report is segmented –

1) By Product Type: Organ Preservation Solution, Transplant Diagnostics, Xeno Products, Other Product Types

2) By Application: Kidney, Heart, Liver, Lung, Other Applications

3) By End-User: Transplant Centers, Hospitals, Other End-Users

Subsegments:

1) By Organ Preservation Solution: Hypothermic Machine Perfusion (HMP) Solutions, Normothermic Machine Perfusion (NMP) Solutions, Static Cold Storage (SCS) Solutions, Oxygenated Perfusion Solutions

2) By Transplant Diagnostics: Histocompatibility Testing, Crossmatching Tests, Molecular Typing (DNA-based Testing), Immunological Monitoring Assays

3) By Xeno Products: Genetically Engineered Donor Organs, Decellularized Organ Scaffolds, Xenogeneic Cellular Therapies, Immunosuppressive Regimens For Xenotransplants

4) By Other Product Types: Organ Transport Devices, Organ Recovery and Preservation Equipment, Surgical Instruments For Transplantation, Post-Transplant Monitoring Devices

What Key Developments And Trends Are Impacting The Cross-Species Organ Transplantation Market?

Leading companies in the cross-species organ transplantation market are concentrating on forming strategic partnerships to expedite the regulatory clearance process for xenotransplantation offerings. A strategic partnership represents a collaboration where entities unite to pursue common aims by harnessing each other’s capabilities and assets, intending to stimulate expansion, creativity, and competitive edge without consolidating. For example, in February 2025, United Therapeutics, a US-based biotechnology company, and eGenesis, a US-based pharmaceutical company, initiated clinical trials for pig kidney (xenotransplant) transplants in humans. This trial secured authorization from the U.S. Food and Drug Administration (FDA) to implant genetically modified pig kidneys into patients experiencing kidney failure. The trials endeavor to tackle the severe scarcity of donor kidneys by potentially furnishing a novel, enduring organ supply for those requiring it.

Which Global Companies Are Actively Competing In The Cross-Species Organ Transplantation Market?

Major companies operating in the cross-species organ transplantation market are Novartis AG, Optipharm Co Ltd, Astellas Pharma Inc., United Therapeutics Corporation, TransMedics Group Inc., Artivion Inc., eGenesis Inc., Organ Recovery Systems Inc., OrganOX Ltd, Paragonix Technologies Inc., Qihan Biotech, PorMedTec Co., XenoTheraputics Inc., Makana Therapeutics Inc., Preservation Solutions Inc., Nzeno Ltd, Infigen Inc., Revivicor Inc., XVIVO Perfusion AB, Bridge To Life Ltd, Transplant Genomics Inc.

Read the full cross-species organ transplantation market report here:

https://www.thebusinessresearchcompany.com/report/cross-species-organ-transplantation-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cross-Species Organ Transplantation Market?

North America was the largest region in the cross-species organ transplantation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cross-species organ transplantation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cross-Species Organ Transplantation Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27267&type=smp

Browse Through More Reports Similar to the Global Cross-Species Organ Transplantation Market 2026, By The Business Research Company

Crohns Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Rare Inflammatory Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795